Pancreatectomy

Cincinnati Children's Ranked #1 in the Nation in U.S. News & World Report's Best Children's Hospitals Rankings

Retrieved on: 
Wednesday, June 21, 2023
Proton, Vaccine, Radiation, Sleep, Diabetes, Pediatric urology, NICU, Indiana University Health Proton Therapy Center, U.S. News & World Report, Proton therapy, Hospital, Acute kidney injury, Clinical trial, Quality of life, Research, Cincinnati Children's Hospital Medical Center, PUV, FLASH, Patient, Patient safety, Risk, Pancreatectomy, Super Soccer Stars, ICU, Health, Grammy Award for Best Children's Music Album, III, News, Urology, Neonatology, Nursing, Dentistry, Pharmaceutical industry, MD, Endocrinology

CINCINNATI, June 21, 2023 /PRNewswire/ -- Cincinnati Children's has been named #1 in the nation in U.S. News & World Report's Best Children's Hospitals 2023-24 rankings.

Key Points: 
  • CINCINNATI, June 21, 2023 /PRNewswire/ -- Cincinnati Children's has been named #1 in the nation in U.S. News & World Report's Best Children's Hospitals 2023-24 rankings.
  • Hospitals were ranked based on key clinical data that includes measures such as patient outcomes, diversity training and patient safety.
  • The goal of these rankings is to identify hospitals that provide the highest quality care for children with the most serious or complicated medical conditions.
  • "We are incredibly proud and honored to be recognized as the best pediatric hospital in the nation," says Steve Davis, MD, MMM, president and CEO of Cincinnati Children's.

Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022

Retrieved on: 
Tuesday, March 21, 2023
University of California, Davis, University, CGT, Marketing, Telephone, UC, Patient, Investment, MOU, Pancreatectomy, Security (finance), FDA, Therapy, Pharmaceutical industry, EU, Labs, Fausto Pocar

GERMANTOWN, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the fourth quarter and year ended December 31, 2022.
  • Vered Caplan, CEO of Orgenesis, said, “I am pleased to report that revenue for the fourth quarter of 2022 increased by 98% to $13.6 million, compared to $6.9 million for the same period last year as we are progressing with the planned rollout of our POCare platform.
  • In addition to our strong revenue growth, we reduced our operating loss by 91% for the fourth quarter of 2022 versus the same period last year, which reflects our cost-effective and highly scalable business model.
  • In 2022, our subsidiary, Koligo Therapeutics, supplied Kyslecel to five medical institutes supplying total pancreatectomy - islet auto transplant (TP-IAT) cases.

Surgical Robots Market worth $18.4 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, January 31, 2023
Neurosurgery, Cholecystectomy, Hospital, Obesity, Surgeon, Growth, Bariatric surgery, Prevalence, General surgery, Heller myotomy, Product-service system, Pancreatectomy, Hospital Clinic Manuel Quintela, Laparoscopy, Gastrectomy, Medical device, Dentistry

In 2021, the robotic systems segment accounted for the second largest share of the surgical robots market.

Key Points: 
  • In 2021, the robotic systems segment accounted for the second largest share of the surgical robots market.
  • The growing focus on adopting technologically advanced surgical robots and instruments among end users has fueled the market growth in this segment.
  • By robotic systems, the surgical robots market has been segmented into laparoscopy robotic systems, orthopedic robotic systems, neurosurgical robotic systems, and other systems.
  • By application, the surgical robots market has been segmented into general surgery, urological surgery, gynecological surgery, orthopedic surgery, neurosurgery, and other applications.

Surgical Robots Market worth $18.4 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, January 31, 2023
Neurosurgery, Cholecystectomy, Hospital, Obesity, Surgeon, Growth, Bariatric surgery, Prevalence, General surgery, Heller myotomy, Product-service system, Pancreatectomy, Hospital Clinic Manuel Quintela, Laparoscopy, Gastrectomy, Medical device, Dentistry

In 2021, the robotic systems segment accounted for the second largest share of the surgical robots market.

Key Points: 
  • In 2021, the robotic systems segment accounted for the second largest share of the surgical robots market.
  • The growing focus on adopting technologically advanced surgical robots and instruments among end users has fueled the market growth in this segment.
  • By robotic systems, the surgical robots market has been segmented into laparoscopy robotic systems, orthopedic robotic systems, neurosurgical robotic systems, and other systems.
  • By application, the surgical robots market has been segmented into general surgery, urological surgery, gynecological surgery, orthopedic surgery, neurosurgery, and other applications.

Children's Hospital of Philadelphia's Congenital Hyperinsulinism Center Celebrates 600 Surgeries

Retrieved on: 
Wednesday, December 21, 2022
Hospital, Surgeon, Diabetes, Patient, Family, History, American Association of Clinical Endocrinologists, Brain, Hypoglycemia, Genetic testing, Disease, Nursing, Children's Hospital of Philadelphia, Hyperinsulinism, Seizure, Diagnosis, Division, Social, Pancreatectomy, Congenital hyperinsulinism, Brain damage, Health, Death, Birth defect, Gene Hatfield, Infant, Pancreas, Prussia, CHOP, Incidence, Insulin, Research, HI, MSCE, Genetics, Health insurance, Pharmaceutical industry, Dentistry, Child, Endocrinology, MD

PHILADELPHIA, Dec. 21, 2022 /PRNewswire/ -- The Congenital Hyperinsulinism (HI) Center at Children's Hospital of Philadelphia (CHOP), the nation's largest and most active center of its kind, is celebrating the completion of 600 pancreatectomies, a surgical procedure that involves removing all or part of the pancreas. The procedure is used to treat some forms of congenital HI, a life-threatening genetic disorder in which the insulin cells of the pancreas, called beta cells, secrete too much insulin, leading to low blood sugar (hypoglycemia).

Key Points: 
  • PHILADELPHIA, Dec. 21, 2022 /PRNewswire/ -- The Congenital Hyperinsulinism (HI) Center at Children's Hospital of Philadelphia (CHOP), the nation's largest and most active center of its kind, is celebrating the completion of 600 pancreatectomies, a surgical procedure that involves removing all or part of the pancreas.
  • Established in 1998, CHOP's HI Center treats children with congenital HI from all over the world.
  • The multidisciplinary team in CHOP's HI Center works together to provide specialized, patient-centered care for children with congenital HI and their families.
  • About Children's Hospital of Philadelphia: A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital.

Surgical Robots Market worth $14.4 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, December 14, 2022
Heller myotomy, Neurosurgery, Growth, Gastrectomy, Cholecystectomy, Bariatric surgery, General surgery, Pancreatectomy, Dentistry

Based on product & service, the surgical robots market is segmented into robotic systems, instruments & accessories, and services.

Key Points: 
  • Based on product & service, the surgical robots market is segmented into robotic systems, instruments & accessories, and services.
  • The instruments & accessories segment accounted for the largest share of 53.8% of the market.
  • The surgical robots market, based on application is segmented into general surgery, urological surgery, gynecological surgery, orthopedic surgery, neurosurgery, and other applications.
  • Growth in this market segment can be attributed to the increased use of surgical robots in general procedures such as bariatric surgery, Heller myotomy, gastrectomy, hernia repair, cholecystectomy, transoral surgery, and pancreatectomy.

Surgical Robots Market worth $14.4 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, December 14, 2022
Heller myotomy, Neurosurgery, Growth, Gastrectomy, Cholecystectomy, Bariatric surgery, General surgery, Pancreatectomy, Dentistry

Based on product & service, the surgical robots market is segmented into robotic systems, instruments & accessories, and services.

Key Points: 
  • Based on product & service, the surgical robots market is segmented into robotic systems, instruments & accessories, and services.
  • The instruments & accessories segment accounted for the largest share of 53.8% of the market.
  • The surgical robots market, based on application is segmented into general surgery, urological surgery, gynecological surgery, orthopedic surgery, neurosurgery, and other applications.
  • Growth in this market segment can be attributed to the increased use of surgical robots in general procedures such as bariatric surgery, Heller myotomy, gastrectomy, hernia repair, cholecystectomy, transoral surgery, and pancreatectomy.

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting

Retrieved on: 
Monday, September 19, 2022
GIR, Time, Safety, Hypoglycemia, Endocrine Society, IV, Child, Hospital, Part, European Society of Gynaecological Oncology, Dasiglucagon, Philadelphia, Glycemia, Patient, CHI, 2021 Essex County Council election, Pancreatectomy, CGM, Diabetes, Congenital hyperinsulinism, Part Two, ESPE, DK, Disease, Medical imaging, Pharmaceutical industry, Vaccine, Medical device, Zealand Pharma, Endocrinology

Though congenital hyperinsulinism is an incredibly challenging disease to manage, the efficacy and safety of dasiglucagon observed in this Phase 3 trial, support its potential as a new treatment option for children with CHI.

Key Points: 
  • Though congenital hyperinsulinism is an incredibly challenging disease to manage, the efficacy and safety of dasiglucagon observed in this Phase 3 trial, support its potential as a new treatment option for children with CHI.
  • We are very pleased to present the compelling results from the Phase 3 study of dasiglucagon in newborns and infants up to 12 months of age at ESPE 2022.
  • This study deepens our understanding of dasiglucagons potential as an innovative treatment for CHI patients, said David Kendall, M.D., Chief Medical Officer of Zealand Pharma.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.

Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)  

Retrieved on: 
Thursday, May 19, 2022
Royal commission, Congenital hyperinsulinism, Medicine, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, European Commission, Nasdaq, Patient, Hypoglycemia, SOC, Dasiglucagon, DK, IV, COVID-19, Failure, Marketing, Research, FDA, Intellectual property, Program, DEKA, Standard of care, Advertising, NDA, Boehringer Ingelheim, Pancreatectomy, AstraZeneca, Zealand Pharma, Medical device, Pharmaceutical industry, CHI

20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced positive top-line results from its second Phase 3 clinical trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI).

Key Points: 
  • 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced positive top-line results from its second Phase 3 clinical trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI).
  • The Phase 3 program for dasiglucagon constitutes the largest clinical development program ever conducted in CHI.
  • In total, 42 of 44 participants enrolled across the dasiglucagon CHI Phase 3 clinical programs continued into the ongoing safety extension trial.
  • We are extremely pleased with the top-line results from our second Phase 3 study of dasiglucagon for the treatment of infants with CHI.

Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update

Retrieved on: 
Wednesday, March 30, 2022
An Act to exempt a particular class of securities from the Securities and Exchange Act, Therapy, Good manufacturing practice, Research, Hospital, CEO, Tel Aviv Sourasky Medical Center, Technology, TILS, Securities Act of 1933, GLOBE, Fausto Pocar, GMP, Annual report, Security (finance), University of Maryland Center for Environmental Science, Pain, Â, Pancreatectomy, Quality of life, Cell, Cyprus Securities and Exchange Commission, Stem cell, JV, NASDAQ, CGT, Survival, Telephone, Microsoft, Diabetes, RISK, Drug Quality and Security Act, Patient, Company, Protest and strikes of the CGT union 2021, Compliance, Johns Hopkins, COVID-19, Traction, Pharmaceutical industry, Online gambling, Labs, EU

(NASDAQ: ORGS) (Orgenesis or the Company), a global biotech company working to unlock the full potential of cell and gene therapies, today reports its financial results for the year ended December 31, 2021 and provides a business update.

Key Points: 
  • (NASDAQ: ORGS) (Orgenesis or the Company), a global biotech company working to unlock the full potential of cell and gene therapies, today reports its financial results for the year ended December 31, 2021 and provides a business update.
  • Vered Caplan, CEO of Orgenesis, said, Orgenesis revenues have increased more than four-fold to $35.5 million for 2021 compared to $7.7 million for 2020.
  • These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict.
  • We undertake no obligation to revise or update any forward-looking statement for any reason.